Home/Filings/4/0001870913-24-000022
4//SEC Filing

Shanmugam Muthusamy 4

Accession 0001870913-24-000022

CIK 0001023024other

Filed

Jun 19, 8:00 PM ET

Accepted

Jun 20, 7:11 PM ET

Size

10.6 KB

Accession

0001870913-24-000022

Insider Transaction Report

Form 4
Period: 2024-06-17
Shanmugam Muthusamy
DirectorHEAD OF R&D, COO-NOVITIUM OPS
Transactions
  • Sale

    Common Stock

    2024-06-18$60.76/sh10,607$644,481714,067 total(indirect: By LLC)
  • Sale

    Common Stock

    2024-06-20$59.86/sh11,447$685,217702,620 total(indirect: By LLC)
  • Sale

    Common Stock

    2024-06-17$61.41/sh7,946$487,964724,674 total(indirect: By LLC)
Holdings
  • Common Stock

    (indirect: By LLC)
    5,000
  • Common Stock

    68,652
Footnotes (6)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.
  • [F2]The shares were sold in multiple trades at prices ranging from $60.77 to $62.55. The price reported above reflects the weighted average sales price.
  • [F3]The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
  • [F4]The shares were sold in multiple trades at prices ranging from $60.33 to $61.82. The price reported above reflects the weighted average sales price.
  • [F5]The shares were sold in multiple trades at prices ranging from $59.40 to $60.50. The price reported above reflects the weighted average sales price.
  • [F6]The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

Issuer

ANI PHARMACEUTICALS INC

CIK 0001023024

Entity typeother

Related Parties

1
  • filerCIK 0001870913

Filing Metadata

Form type
4
Filed
Jun 19, 8:00 PM ET
Accepted
Jun 20, 7:11 PM ET
Size
10.6 KB